Products

LATS1/2 rabbit pAb
One-click to copy product information
ES2704
Size: Price:
50 µL $148.00
100 µL $248.00

Overview

Product name: LATS1/2 rabbit pAb
Reactivity: Human;Mouse
Alternative Names: LATS1; WARTS; Serine/threonine-protein kinase LATS1; Large tumor suppressor homolog 1; WARTS protein kinase; h-warts; LATS2; KPM; Serine/threonine-protein kinase LATS2; Kinase phosphorylated during mitosis protein; Large tumor suppressor ho
Source: Rabbit
Dilutions: Western Blot: 1/500 - 1/2000. IHC-p: 1:100-300 ELISA: 1/20000. IF 1:100-300 Not yet tested in other applications.
Immunogen: The antiserum was produced against synthesized peptide derived from human LATS1/2. AA range:1041-1090
Storage: -20°C/1 year
Clonality: Polyclonal
Isotype: IgG
Concentration: 1 mg/ml
Observed Band: 130-140kD
GeneID: 9113/26524
Human Swiss-Prot No: O95835/Q9NRM7
Cellular localization: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, spindle . Midbody . Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body . Localizes to the centrosomes throughout interphase but migrates to the mitotic apparatus, including spindle pole bodies, mitotic spindle, and midbody, during mitosis. .
Background: The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatmen